US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Articles published by Entrada Therapeutics, Inc.

< Previous 1 2 Next >
News headline image
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Reports First Quarter 2026 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Reports Third Quarter 2025 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers BIIB TRDA
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Reports First Quarter 2025 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
News headline image
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
< Previous 1 2 Next >